Nav: Home

Reporting of clinical trial results by top academic centers remains poor

February 17, 2016

Dissemination of clinical trial results by leading academic medical centres in the United States remains poor, despite ethical obligations - and sometimes statutory requirements - to publish findings and report results in a timely manner, concludes a study in The BMJ this week.

Researchers found that only 29% of completed clinical trials led by investigators at major US academic centers were published within two years of completion and only 13% reported results on the largest clinical trial registry, ClinicalTrials.gov.

They say action is needed to rectify this lack of timely reporting and publication, "as they impair the research enterprise and threaten to undermine evidence based clinical decision making."

Randomized clinical trials are the ideal means for evaluating the efficacy and safety of medical drugs and devices.

Timely dissemination of trial results is required to honor the commitment of study participants, advance the scientific process, and improve clinical care, but little is known about the performance of academic medical centers in this endeavor.

US law also requires that certain trials be registered and their results posted.

Yet previous studies have shown that between 25% and 50% of clinical trials remain unpublished, sometimes years after completion, and that the results of many trials are not reported promptly on trial registries.

So, a team led by Professor Harlan Krumholz at Yale School of Medicine, examined rates of publication and reporting of results within two years for 4,347 registered trials completed between October 2007 and September 2010 across 51 leading US academic institutions.

Results show that only 29% (1,245/4,347) of completed clinical trials led by investigators at major US academic centers were published within two years of study completion and only 13% (547/4,347) reported results on ClinicalTrials.gov.

The study also revealed marked variation in rates of dissemination of clinical trial results across academic institutions, with more than a twofold variation in the average time from study completion to dissemination of results and more than a threefold variation in the rate of dissemination across institutions.

However, no academic center published more than 40% of completed clinical trials within two years of completion or reported results for more than 41% of its trials.

"We found noticeable variation and poor performance across leading academic medical centers in the dissemination of clinical trial results," write the authors. And they point out that there is "no effective enforcement mechanism and no repercussions to academic institutions or individual investigators" for failing to report results.

"The lack of timely reporting and publication fundamentally impairs the research enterprise, violates the commitment made by investigators to patients and funders, squanders precious time and resources, and threatens to compromise evidence based clinical decision making," they conclude.
-end-


BMJ

Related Clinical Trial Results Articles:

BIOCAD presents results of clinical trial proving efficacy of netakimab at EULAR 2020
BIOCAD presents results of clinical trial proving efficacy of netakimab in the treatment of psoriatic arthritis at the Annual European Congress of Rheumatology (EULAR 2020).
Malaria: Vaccine clinical trial for pregnant women yields promising results
Malaria infection during pregnancy represents a major public health problem in the regions endemic for the disease, substantially increasing the risks to mothers and their unborn children.
First clinical trial of drug-inducible gene therapy yields encouraging preliminary results
A new clinical trial by investigators from Brigham and Women's Hospital and Dana-Farber Cancer Institute set out to test the safety and effectiveness of controlling a powerful immunotherapy, known as human interleukin-12 (hIL-12), by using an oral activator -- a drug that can give finer control over when a gene gets turned on -- in patients with recurrent glioblastoma.
Promising clinical trial results for drug for rare disease in which patients can't eat fat
In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could also help inform better prevention methods and treatments for many types of heart disease.
CBD clinical trial results on seizure frequency in dogs 'encouraging'
Dr. Stephanie McGrath found in a small study that 89 percent of dogs who received CBD in the clinical trial had a reduction in the frequency of seizures.
WINTHER trial results
Published in Nature Medicine, results of WINTHER, the first study pioneered by the WIN Consortium -- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial -- shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.
New glioblastoma vaccine shows promising results in phase Ib clinical trial
A brain-cancer vaccine more than 20 years in the making suspends cancer growth in patients enrolled in early-stage trial.
Results of ABATE infection trial published
Daily bathing with an antiseptic soap, plus nasal ointment for patients with prior antibiotic resistant bacteria, reduced hospital acquired infections among patients with central venous catheters and other devices that pierce the skin, according to results of the ABATE Infection Trial.
Dana-Farber researchers report clinical trial results in treatment of leukemia & lymphoma
New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting.
Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer
Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months.
More Clinical Trial Results News and Clinical Trial Results Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#566 Is Your Gut Leaking?
This week we're busting the human gut wide open with Dr. Alessio Fasano from the Center for Celiac Research and Treatment at Massachusetts General Hospital. Join host Anika Hazra for our discussion separating fact from fiction on the controversial topic of leaky gut syndrome. We cover everything from what causes a leaky gut to interpreting the results of a gut microbiome test! Related links: Center for Celiac Research and Treatment website and their YouTube channel
Now Playing: Radiolab

The Flag and the Fury
How do you actually make change in the world? For 126 years, Mississippi has had the Confederate battle flag on their state flag, and they were the last state in the nation where that emblem remained "officially" flying.  A few days ago, that flag came down. A few days before that, it coming down would have seemed impossible. We dive into the story behind this de-flagging: a journey involving a clash of histories, designs, families, and even cheerleading. This show is a collaboration with OSM Audio. Kiese Laymon's memoir Heavy is here. And the Hospitality Flag webpage is here.